SigTuple

AI, robotics, microfluidics and high-resolution microscopy combined to automate microscopic analysis of biological samples.

Browser-based review lets pathologists work from anywhere, addressing India's shortage of on-site pathologists.

AI100 is FDA- and CE-cleared; positioned as the world's only automated AI-powered multi-purpose digital cell morphology analyser for both peripheral blood smear and urine sediment.

Customer testimonial from HCG's Executive Chairman on adopting AI100 across the hospital chain's Hematopathology labs.

Served via the AS76 digital cell morphology analyser for peripheral blood smear.

Served via the AI100 multi-purpose digital microscope for blood and urine analysis.

HealthCare Global Enterprises Ltd (HCG) deployed AI100 across its Hematopathology labs network-wide.

Krsnaa Diagnostics tied up with SigTuple to digitise its pathology lab network, starting with Punjab, Himachal Pradesh and Maharashtra.

SigVet is a multi-test, AI-powered point-of-care platform for veterinary clinics.

Personalised walkthroughs focused on the customer's specific use case and workflow, with clinical and product specialists available for Q&A.

Prospective lab customers book a live, personalised online demonstration with a product specialist.

HORIBA and its affiliates distribute AI100 across the Indian subcontinent.

Onboarded as a medical device distributor for sales and service in India, alongside HORIBA Medical.

Local distributor for SigTuple's expansion into the Indonesian market.

Beyond AI100, SigTuple's R&D is developing a multi-use laboratory device that could handle more test types (potentially microbiology, pap smears, and biopsies) from the same hardware, plus a separate microfluidics-based point-of-care device.

Pursues regulatory clearances (including US FDA approval) required to enter new geographic markets, on top of certifications already held.

Core product engineering is focused on a product that holistically addresses and automates all forms of microscopy performed in clinical laboratories, from sample imaging through AI classification.

Expands into new geographies and adds product lines, with partnerships and product launches planned across Southeast Asia, MENA, Europe and North America, alongside entry into the point-of-care microfluidics segment.

27 granted patents in the US and India, per SigTuple's own disclosure — one of the more robust IP portfolios among Indian medtech startups.

Over a decade of R&D and 30+ publications underpin the AI/robotics/microfluidics stack.

Partnership to accelerate adoption of AI100 across the Indian subcontinent, with HORIBA distributing the device.

HealthCare Global Enterprises Ltd equipped its Hematopathology labs network-wide with AI100.

Krsnaa tied up with SigTuple to digitise its pathology lab network via a tele-pathology reporting centre in Pune.

AI100 deployed across major Indian laboratory and hospital chains including Manipal and SRL, alongside HCG.

Thyrocare deployed AI100 to automate its manual microscopy process, with pilot installations at its Lucknow, Nagpur and Ranchi labs.

SigTuple's primary revenue driver is selling its automated digital microscope hardware (e.g. the AI100) outright to diagnostic laboratories.

Once a device is deployed, SigTuple collects ongoing service fees for the AI diagnostic software that runs on the hardware to classify blood and urine cell images.

Where labs cannot afford to buy the microscope outright, SigTuple rents the device instead of selling it, lowering the adoption barrier in disadvantaged settings.

SigTuple's total reported expenses were ₹26.8 Cr for FY24-25 (year ended March 31, 2025), roughly flat versus the prior year (-1%) even as revenue grew, per financial data compiled from the company's Registrar-of-Companies filings.